SCHEMBL352240

SCHEMBL352240

COc1nc2ccccc2cc1C(=O)NC1=CC(=O)C2OC2C1=O

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36
TP53 P04637 1/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
CASP3 P42574 1/20 0.36
ATM Q13315 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
BTK Q06187 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL352275 0.84 SMN1; SMN2 (0.37) MAPTRAB9ASMN1; SMN2MAOBNPC1
SCHEMBL352431 0.79 PARK7 (0.56) MAPTRAB9ASMN1; SMN2MAOAMAOB
SCHEMBL16650575 0.78 IRAK4 (0.45) MAPTRAB9ASMN1; SMN2NPC1POLB
SCHEMBL354123 0.78 BRD4 (0.44) MAPTRAB9ASMN1; SMN2TP53NPC1
SCHEMBL15945345 0.75 MAPT (0.55) MAPTRAB9ASMN1; SMN2TP53NPC1
SCHEMBL15945346 0.74 SMN1; SMN2 (0.50) MAPTRAB9ASMN1; SMN2PPARDPPARA
SCHEMBL352796 0.73 EGLN1 (0.47) MAPTRAB9ANPC1POLBCASP3
SCHEMBL15563826 0.72 ALDH1A1 (0.52) MAPTRAB9ASMN1; SMN2MAOBPPARD
SCHEMBL11218527 0.72 MAPT (0.47) MAPTRAB9ASMN1; SMN2PPARDPPARA
SCHEMBL6603045 0.71 KDM4E (0.51) MAPTRAB9ASMN1; SMN2PPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP claimed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US claimed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US claimed
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP disclosed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US disclosed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015952-A1 Inhibitors of NF-KB NFKBIA, IKBKB, IKBKG MAPT 2761/4885RAB9A 2089/4885SMN1; SMN2 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.